🔥🐔 BizChicken 🐔🔥

Companies Similar to Sonnet BioTherapeutics Holdings, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Bio-Path Holdings, Inc.

Bio-Path Holdings, Inc. logo
Market Cap: Lowest
Employees: Lowest

DNAbilize

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused RNAi nano particle drug development company, developing products based on the DNAbilize technology. The company is advancing its lead drug candidate, prexigebersen, for the treatment of AML and myelodysplastic syndrome.

Tags: Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, DNAbilize, Drug Development, Lymphoma, Myelodysplastic Syndrome, Oncology, Pancreatic Cancer, Prexigebersen, RNAi

Symbol: BPTH

Recent Price: $1.17

Industry: Biotechnology

CEO: Mr. Peter H. Nielsen MBA

Sector: Healthcare

Employees: 10

Address: 4710 Bellaire Boulevard, Bellaire, TX 77401

Phone: 832 742 1357

Leadership

  • Peter Nielsen, Chief Executive Officer, Chief Financial Officer
  • Ana Tari Ashizawa, PhD, MBA, Senior Vice President of Research, Development & Clinical Design
  • Anthony Price, MBA, Senior Vice President of Finance, Accounting & Administration
  • Michael Hickey, MBA, Vice President of Clinical Operations
  • Michael Roberts, Director of Manufacturing Planning & Engineering
  • Chairman of the Board,
  • President,
  • Heath Cleaver, Director
  • Paul Aubert, Director
  • Douglas P. Morris, Director
  • Aline Sherwood, Director

Last updated: 2024-12-31

Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc. logo
Market Cap: Lowest
Employees: Lowest

LB-100 series and LB-200 series

Lixte Biotechnology Holdings, Inc. is a drug discovery company leveraging biomarker technology to develop enzyme-targeting drugs for cancer, vascular, metabolic, hereditary, and neurodegenerative diseases.

Tags: biomarker technology, biotechnology, cancer treatment, drug discovery, enzyme targets

Symbol: LIXT

Recent Price: $2.00

Industry: Biotechnology

CEO: Mr. Bastiaan van der Baan M.Sc.

Sector: Healthcare

Employees: 3

Address: 680 East Colorado Boulevard, Pasadena, CA 91101

Phone: 631 830 7092

Last updated: 2024-12-31

PharmaCyte Biotech, Inc.

PharmaCyte Biotech, Inc. logo
Market Cap: Lowest
Employees: Lowest

Cell-in-a-Box

Pharma Cyte Biotech, Inc. is a biotechnology company focused on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites. Their therapies are based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology, used for treating various cancers and diabetes.

Tags: Cell-in-a-Box, biotechnology, cancer, cannabis plant, cellular therapies, diabetes, insulin-dependent diabetes, live cell encapsulation, pancreatic cancer

Symbol: PMCB

Recent Price: $1.55

Industry: Biotechnology

CEO: Mr. Joshua N. Silverman

Sector: Healthcare

Employees: 2

Address: 3960 Howard Hughes Parkway, Las Vegas, NV 89169

Phone: 917 595 2850

Leadership

  • Joshua N. Silverman, Independent Director
  • Dr. Michael M. Abecassis, Independent Director
  • Robert Weinstein, Director
  • Wayne R. Walker, Director
  • Jonathan L. Schechter, Independent Director
  • Dr. Abecassis, Director
  • Kenneth L. Waggoner, Independent Director
  • Daniel C. Farb, Independent Director
  • Daniel C. Allen, Independent Director
  • Jack E. Stover, Independent Director

Last updated: 2024-12-31

Oncternal Therapeutics, Inc.

Oncternal Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

zilovertamab, ONCT-216, ONCT-808, ONCT-534

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in oncology therapies for cancers with significant unmet medical needs, featuring a pipeline that includes the monoclonal antibody zilovertamab and various other targeted treatments.

Tags: CAR-T, ROR1, antibody, biopharmaceutical, cancer therapy, clinical-stage, oncology

Symbol: ONCT

Recent Price: $0.53

Industry: Biotechnology

CEO: Dr. James B. Breitmeyer M.D., Ph.D.

Sector: Healthcare

Employees: 27

Address: 12230 El Camino Real, San Diego, CA 92130

Phone: 858 434 1113

Last updated: 2024-12-31

Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp. logo
Market Cap: Lowest
Employees: Low

TNX-1500, TNX-2900, TNX-801, TNX-1840, TNX-1850, TNX-3500

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company that focuses on developing therapies for immunology, rare diseases, infectious diseases, and central nervous system disorders. Key products include TNX-1500 for organ transplant and autoimmune diseases, TNX-2900 for Prader-Willi syndrome, and TNX-801 for smallpox prevention.

Tags: CNS, autoimmunity, biopharmaceutical, cancer, immunology, infectious disease, rare disease, therapeutics

Symbol: TNXP

Recent Price: $0.36

Industry: Biotechnology

CEO: Dr. Seth Lederman M.D.

Sector: Healthcare

Employees: 103

Address: 26 Main Street, Chatham, NJ 07928

Phone: 862 799 8599

Last updated: 2024-12-31

Aileron Therapeutics, Inc.

Aileron Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

ALRN-6924

Aileron Therapeutics, Inc. is a clinical stage oncology company developing ALRN-6924 for various cancer treatments, with multiple clinical trials in progress.

Tags: ALRN-6924, cancer therapies, chemoprotection, clinical stage, clinical trials, oncology

Symbol: ALRN

Recent Price: $2.32

Industry: Biotechnology

CEO: Dr. James Brian Windsor Ph.D.

Sector: Healthcare

Employees: 15

Address: 285 Summer Street, Boston, MA 02210

Phone: 617 995 0900

Last updated: 2024-12-31

ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc. logo
Market Cap: Low
Employees: Low

ALX148

ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company developing therapies for cancer patients. Its lead product, ALX148, targets CD47 and is in trials for various cancers. The company also explores pre-clinical treatments like ALTA-002 to enhance immune response to cancer.

Tags: CD47, cancer therapy, clinical trials, collaboration, immuno-oncology, solid tumors

Symbol: ALXO

Recent Price: $1.66

Industry: Biotechnology

CEO: Mr. Jason W. Lettmann

Sector: Healthcare

Employees: 81

Address: 323 Allerton Avenue, South San Francisco, CA 94080

Phone: 650 466 7125

Last updated: 2024-12-31

Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

BDC-1001

Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing immuno-oncology agents that target tumor cells for immune system elimination.

Tags: HER2, biotechnology, cancer treatment, clinical-stage, immuno-oncology

Symbol: BOLT

Recent Price: $0.57

Industry: Biotechnology

CEO: Mr. William P. Quinn

Sector: Healthcare

Employees: 100

Address: 900 Chesapeake Drive, Redwood City, CA 94063

Phone: 650 665 9295

Last updated: 2024-12-31

Compass Therapeutics, Inc.

Compass Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

CTX-009, CTX-471, CTX-8371

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics to treat various human diseases. Their clinical stage products include investigational bispecific antibodies like CTX-009 and monoclonal antibodies such as CTX-471.

Tags: CTX-009, CTX-471, CTX-8371, antibody therapeutics, biopharmaceutical, clinical stage, oncology

Symbol: CMPX

Recent Price: $1.48

Industry: Biotechnology

CEO: Dr. Thomas J. Schuetz M.D., Ph.D.

Sector: Healthcare

Employees: 32

Address: 80 Guest Street, Boston, MA 02135

Phone: 617 500 8099

Last updated: 2024-12-31

Heron Therapeutics, Inc.

Heron Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

SUSTOL, CINVANTI, ZYNRELEF

Heron Therapeutics, Inc. is a biotechnology company focused on developing treatments to address unmet patient needs, utilizing its proprietary Biochronomer drug delivery technology.

Tags: biotechnology, cancer treatment, chemotherapy, drug delivery, nausea prevention

Symbol: HRTX

Recent Price: $1.51

Industry: Biotechnology

CEO: Mr. Craig Alexander Collard

Sector: Healthcare

Employees: 126

Address: 4242 Campus Point Court, San Diego, CA 92121

Phone: 858 251 4400

Leadership

  • Adam Morgan, Chairman
  • Sharmila Dissanaike, M.D., FACS, FCCM, Director
  • Craig Johnson, Lead Independent Director
  • Susan Rodriguez, Director
  • Christian Waage, Director
  • Craig Collard, Director
  • Brett Fleshman, Chief Business Officer

Last updated: 2024-12-31

Lantern Pharma Inc.

Lantern Pharma Inc. logo
Market Cap: Lowest
Employees: Lowest

LP-100

Lantern Pharma Inc. is a clinical stage biotechnology company focused on using artificial intelligence, machine learning, and genomic data to streamline drug development, with key drug candidates including LP-100, LP-300, and LP-184 for various cancer treatments.

Tags: artificial intelligence, biotechnology, cancer treatment, drug development, genomic data, machine learning

Symbol: LTRN

Recent Price: $3.27

Industry: Biotechnology

CEO: Mr. Panna Sharma PH.D.

Sector: Healthcare

Employees: 21

Address: 1920 McKinney Avenue, Dallas, TX 75201

Phone: 972 277 1136

Last updated: 2024-12-31

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. logo
Market Cap: High
Employees: Low

NX-2127, NX-5948, NX-1607, NX-0255

Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.

Tags: BTK degrader, CBL-B inhibitor, biopharmaceutical, cancer, clinical trials, immune disorders

Symbol: NRIX

Recent Price: $18.64

Industry: Biotechnology

CEO: Dr. Arthur T. Sands M.D., Ph.D.

Sector: Healthcare

Employees: 284

Address: 1700 Owens Street, San Francisco, CA 94158

Phone: 415 660 5320

Last updated: 2024-12-31

Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. logo
Market Cap: Low
Employees: Lowest

Back Beat Cardiac Neuromodulation Therapy (CNT), Virtue Sirolimus Angio Infusion Balloon (SAB)

Orchestra Bio Med Holdings, Inc. is a biomedical innovation company specializing in treatments for hypertension and atherosclerotic artery disease, with strategic collaborations with Medtronic and Terumo Corporation.

Tags: atherosclerotic artery disease, biomedical, hypertension, innovation, minimally invasive surgery, strategic partnership

Symbol: OBIO

Recent Price: $4.25

Industry: Biotechnology

CEO: Mr. David P. Hochman

Sector: Healthcare

Employees: 56

Address: 150 Union Square Drive, New Hope, PA 18938

Phone: 215 862 5797

Last updated: 2024-12-31

Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

ONS-5010

Outlook Therapeutics, Inc. is a late clinical-stage biopharmaceutical company focused on developing and commercializing monoclonal antibodies for ophthalmic indications, with its lead product candidate ONS-5010 in Phase-III clinical trial for treating wet age-related macular degeneration and other retina diseases.

Tags: biopharmaceutical, clinical trial, monoclonal antibodies, ophthalmic, retina diseases

Symbol: OTLK

Recent Price: $1.86

Industry: Biotechnology

CEO: Mr. C. Russell Trenary III

Sector: Healthcare

Employees: 24

Address: Building F, Iselin, NJ 08852

Phone: 609 619 3990

Leadership

  • Randy Thurman, Executive Chairman
  • Yezan Haddadin, Member of the Board of Directors
  • Kurt J. Hilzinger, Member of the Board of Directors
  • Julia A. Haller, MD, Member of the Board of Directors
  • C. Russell Trenary III, President, Chief Executive Officer, and Member of the Board
  • Lawrence A. Kenyon, Chief Financial Officer and Member of the Board
  • Faisal G. Sukhtian, Executive Director
  • Julian Gangolli, Member of the Board of Directors
  • Gerd Auffarth, MD, Member of the Board of Directors
  • Andong Huang, Vice President, Business Development

Last updated: 2024-12-31

PDS Biotechnology Corporation

PDS Biotechnology Corporation logo
Market Cap: Low
Employees: Lowest

PDS0101

PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company focused on developing multifunctional cancer immunotherapies. Its lead product candidate, PDS0101, is in Phase II clinical trial for treating various human papillomavirus-associated malignancies.

Tags: biopharmaceutical, cancer immunotherapies, clinical trials, clinical-stage, oncology, vaccines

Symbol: PDSB

Recent Price: $1.69

Industry: Biotechnology

CEO: Dr. Frank K. Bedu-Addo Ph.D.

Sector: Healthcare

Employees: 25

Address: 25B Vreeland Road, Florham Park, NJ 07932

Phone: 800 208 3343

Leadership

  • Frank Bedu-Addo, Ph.D., Chief Executive Officer, Director
  • Stephan Toutain, Chief Operating Officer
  • Lars Boesgaard, Chief Financial Officer
  • Gregory Conn, Ph.D., Chief Scientific Officer
  • Kirk Shepard, M.D., Chief Medical Officer
  • Spencer Brown, Senior Vice-President, General Counsel, Corporate Secretary and Compliance Officer
  • Rory Cullinane, Vice President of Quality
  • Joe Dervan, Ph.D., Vice President of Research and Development
  • David Schaaf, M.D., Vice President of Medical Affairs
  • Sir Richard Sykes, Director
  • Ilian Iliev, Ph.D., Director
  • Gregory Freitag, J.D., CPA, Director
  • Otis W. Brawley, M.D., Director
  • Kamil Ali-Jackson, J.D., Director
  • Stephen Glover, Chairman

Last updated: 2024-12-31

Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc. logo
Market Cap: Low
Employees: Low

Rani Pill

Rani Therapeutics Holdings, Inc. is a clinical stage biotherapeutics company focused on developing orally administered biologics with its Rani Pill platform, aimed at replacing subcutaneous or IV injections. The company has multiple products in various stages of development targeting conditions like neuroendocrine tumors, psoriatic arthritis, osteoporosis, growth hormone deficiency, hypoparathyroidism, and type 2 diabetes.

Tags: Rani Pill, biologics, biotherapeutics, clinical trials, healthcare, pharmaceuticals

Symbol: RANI

Recent Price: $1.48

Industry: Biotechnology

CEO: Mr. Talat Imran

Sector: Healthcare

Employees: 140

Address: 2051 Ringwood Avenue, San Jose, CA 95131

Phone: 408 457 3700

Leadership

  • Talat Imran, Chief Executive Officer
  • Mir Imran, Founder and Executive Chairman
  • Mir Hashim, Chief Scientific Officer
  • Svai Sanford, Chief Financial Officer
  • Eric Groen, General Counsel
  • Kate McKinley, Chief Business Officer
  • Jacques Van Dam, Vice President, Medical Affairs
  • Alireza Javadi, VP of Technical Operations
  • Betsy Gutierrez, Vice President, Quality Assurance
  • Bella Vazquez, Vice President, Human Resources
  • Kyle Horlen, VP of Nonclinical Development & Safety Assessment
  • Arvinder Dhalla, Vice President, Clinical Development
  • Andrew Farquharson, Managing Director, VHM and InCube Ventures
  • Maulik Nanavaty, CEO of Anumana
  • Jean-Luc Butel, Director at Takeda, Novo Holdings, and SG Innovate
  • Laureen DeBuono, Managing Partner, FLG Partners
  • Dennis Ausiello, Director of CATCH & Former Chief of Medicine, Mass General
  • Lisa Rometty, President, CVS Kidney Care

Last updated: 2024-12-31

Soligenix, Inc.

Soligenix, Inc. logo
Market Cap: Lowest
Employees: Lowest

SGX301 (Hy Bryte), SGX942, SGX203, SGX302

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases, operating in the Specialized Bio Therapeutics and Public Health Solutions segments.

Tags: Crohn's disease, SGX301, SGX942, biopharmaceutical, oral mucositis, psoriasis, rare diseases

Symbol: SNGX

Recent Price: $2.91

Industry: Biotechnology

CEO: Dr. Christopher J. Schaber Ph.D.

Sector: Healthcare

Employees: 13

Address: 29 Emmons Drive, Princeton, NJ 08540

Phone: 609 538 8200

Leadership

  • Christopher J. Schaber, PhD, Chairman, President and Chief Executive Officer
  • Gregg A. Lapointe, CPA, MBA, Board Director
  • Diane L. Parks, MBA, Board Director
  • Robert J. Rubin, MD, Board Director
  • Jerome Zeldis, MD, PhD, Board Director

Last updated: 2024-12-31

Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Holdings, Inc. logo
Market Cap: Lowest
Employees: Lowest

SON-1010, SON-080

Sonnet Bio Therapeutics Holdings, Inc. is a clinical stage oncology-focused biotechnology company developing biologic medicines using its human albumin binding technology. The company is based in Princeton, New Jersey, and has lead candidates such as SON-1010 for non-small cell lung cancer, and SON-080 for neuropathies.

Tags: albumin binding technology, biologic medicines, biotechnology, interleukin 12, interleukin 6, oncology

Symbol: SONN

Recent Price: $1.48

Industry: Biotechnology

CEO: Dr. Pankaj Mohan Ph.D.

Sector: Healthcare

Employees: 12

Address: 100 Overlook Center, Princeton, NJ 08540

Phone: 609-375-2227

Leadership

  • Pankaj Mohan, Ph.D., Founder, CEO & Chairman
  • Jay Cross, Chief Financial Officer
  • John K. Cini, Ph.D., Chief Scientific Officer & Co-Founder
  • Susan Dexter, Chief Technical Officer
  • Richard Kenney, M.D., Chief Medical Officer
  • Albert Dyrness, Board Member
  • Nailesh Bhatt, Chief Executive Officer & Board Member
  • Raghu Rao, Board Member
  • Donald Griffith, Financial Controller
  • Lori McNeill, Board Member

Last updated: 2024-12-31

Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. logo
Market Cap: Medium
Employees: Low

TERN-101, TERN-201, TERN-501, TERN-601

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for non-alcoholic steatohepatitis (NASH) and obesity, incorporating products like TERN-101, TERN-201, TERN-501, and TERN-601.

Tags: NASH, biopharmaceutical, clinical trials, obesity, pharmaceutical research

Symbol: TERN

Recent Price: $7.15

Industry: Biotechnology

CEO: Ms. Amy L. Burroughs M.B.A.

Sector: Healthcare

Employees: 66

Address: 1065 East Hillsdale Boulevard, Foster City, CA 94404

Phone: 650 525 5535

Last updated: 2024-11-08

Tango Therapeutics, Inc.

Tango Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

TNG908

Tango Therapeutics, Inc. is a biotechnology company focused on discovering and developing drugs for cancer treatment, with a lead program TNG908 targeting cancers with methylthioadenosine phosphorylase deletions. The company also works on therapies for BRCA1/2-mutant and STK11-mutant cancers and collaborates with Gilead Sciences, Inc.

Tags: BRCA1/2-mutant cancers, Gilead Sciences, STK11-mutant cancers, TNG908, biotechnology, cancer treatment, drug development, methylthioadenosine phosphorylase, protein arginine methyltransferase 5, strategic collaboration, synthetic lethal

Symbol: TNGX

Recent Price: $3.10

Industry: Biotechnology

CEO: Dr. Barbara L. Weber M.D.

Sector: Healthcare

Employees: 140

Address: 100 Binney Street, Cambridge, MA 02142

Phone: 857 320 4900

Last updated: 2024-12-31